Copyright
©The Author(s) 2016.
World J Gastrointest Oncol. Mar 15, 2016; 8(3): 248-257
Published online Mar 15, 2016. doi: 10.4251/wjgo.v8.i3.248
Published online Mar 15, 2016. doi: 10.4251/wjgo.v8.i3.248
Table 3 Ongoing adjuvant trials
Trial | Registration No. | Treatment groups | Patients planned |
ESPAC-4 | ISRCTN96397434 | Gem + capecitabine | 732 |
Gem | |||
APACT | NCT01964430 | Gem + nab-paclitaxel | 800 |
Gem | |||
ACCORD24 | NCT01526135 | FOLFIRINOX | 490 |
Gem | |||
RTOG-0848 | NCT01013649 | Gem + RCT (capecitabine or 5-FU) | 950 |
Gem | |||
Algenpantucel Immunotherapy | NCT01072981 | Gem ± RCT + Algenpantucel-I vaccine | 722 |
Gem ± RCT |
- Citation: Sinn M, Bahra M, Denecke T, Travis S, Pelzer U, Riess H. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. World J Gastrointest Oncol 2016; 8(3): 248-257
- URL: https://www.wjgnet.com/1948-5204/full/v8/i3/248.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v8.i3.248